Although pharmaceutical companies as a group are keeping pace with the broader market, there is considerable divergence in individual names.
Here's a trade idea for Aurinia Pharmaceuticals.
Here's what I think we'll see up ahead.
These names are displaying both quantitative and technical deterioration.
The stock has been in a weak trend for more than a year.
The pharmaceutical giant gained an analyst's buy recommendation but its technical signals are lackluster at best.
The charts give a reading of weakness ahead for this pharma name.
If you're a long-term BMY bull, here's what the charts suggest.
The biotech giant's charts have displayed weakness of late as it prepares to report fourth-quarter results.
The stock is already down about 15% in 2023 as the pharmaceutical giant gets set to report earnings.